Clinical Trial Update: A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD) [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of ABT-089 in adults with ADHD has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• ABT-089

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Attention Deficit Hyperactivity Disorder | Phase 2 | Status: COMPLETED